NCT00141921

Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque Psoriasis

An Open-Label Extension Study to Evaluate the Safety of Etanercept in Pediatric Subjects With Plaque Psoriasis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 182 (actual)
• Sponsor: Amgen · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the long-term safety and efficacy of etanercept in pediatric patients with moderate to severe psoriasis.

Detailed description

This study was a multicenter, open-label extension study for pediatric patients who participated in Study 20030211 (NCT00078819).

Conditions

• Pediatric Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	Etanercept	Open-label at a dose of 0.8 mg/kg (up to an intended dose of 50 mg) given once weekly by subcutaneous injection

Timeline

• Start date: 2005-08-11
• Primary completion: 2011-12-19
• Completion: 2017-08-16
• First posted: 2005-09-02
• Last updated: 2017-10-05
• Results posted: 2017-02-10